Daiichi Sankyo Company, Limited (DSKYF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Daiichi Sankyo Company, Limited (DSKYF) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 55/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026Daiichi Sankyo Company, Limited (DSKYF) Resumen de Asistencia Médica y Tuberías
Daiichi Sankyo Company, Limited, a Japanese pharmaceutical company, develops and markets a diverse range of drugs including oncology treatments, cardiovascular medications, and vaccines. With a global presence and a focus on innovative therapies like antibody drug conjugates, Daiichi Sankyo maintains a significant position in the competitive pharmaceutical landscape.
Tesis de Inversión
Daiichi Sankyo presents a compelling investment case based on its established position in the pharmaceutical industry, diverse product portfolio, and focus on innovative therapies. The company's oncology franchise, particularly Enhertu, is a key growth driver. With a P/E ratio of 17.85 and a profit margin of 14.8%, Daiichi Sankyo demonstrates financial stability. The company's dividend yield of 2.35% offers an additional incentive for investors. Upcoming catalysts include potential regulatory approvals for new indications of existing drugs and advancements in its research and development pipeline. However, potential risks include competition from other pharmaceutical companies and regulatory challenges. The company's beta of -0.30 suggests lower volatility compared to the overall market.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $32.32B reflects Daiichi Sankyo's significant size and established position in the pharmaceutical industry.
- P/E Ratio of 17.85 indicates the company's valuation relative to its earnings.
- Profit Margin of 14.8% demonstrates the company's ability to generate profit from its revenue.
- Gross Margin of 77.5% showcases the efficiency of Daiichi Sankyo's operations and the value of its products.
- Dividend Yield of 2.35% provides investors with a steady income stream.
Competidores y Pares
Fortalezas
- Strong oncology pipeline with promising new therapies.
- Established presence in key therapeutic areas.
- Global distribution network.
- Experienced management team.
Debilidades
- Reliance on a limited number of key products.
- Exposure to generic competition.
- High research and development costs.
- Dependence on regulatory approvals.
Catalizadores
- Ongoing: Potential regulatory approvals for new indications of existing drugs.
- Ongoing: Advancements in the research and development pipeline, particularly in oncology.
- Ongoing: Expansion into emerging markets.
- Ongoing: Strategic partnerships and acquisitions.
- Ongoing: Growth in the oncology market.
Riesgos
- Potential: Intense competition from other pharmaceutical companies.
- Potential: Patent expirations.
- Potential: Regulatory challenges.
- Potential: Economic downturns.
- Ongoing: Reliance on a limited number of key products.
Oportunidades de crecimiento
- Expansion of Enhertu: Enhertu, Daiichi Sankyo's anti-HER2 antibody drug conjugate, presents a substantial growth opportunity. The global market for HER2-positive breast cancer therapies is significant, and Enhertu's efficacy has positioned it as a leading treatment option. Further expansion into other HER2-expressing cancers, such as non-small cell lung cancer, could significantly increase its market potential. The collaboration with Guardant Health to develop companion diagnostics will further enhance Enhertu's adoption and effectiveness. Timeline: Ongoing.
- Development of New Oncology Therapies: Daiichi Sankyo's commitment to oncology research and development provides a strong foundation for future growth. The company's pipeline includes several promising new cancer therapies targeting various mechanisms of action. Successful development and commercialization of these therapies could drive significant revenue growth and strengthen Daiichi Sankyo's position in the oncology market. The global oncology market is projected to reach $300 billion by 2025. Timeline: Ongoing.
- Geographic Expansion: Expanding into emerging markets represents a significant growth opportunity for Daiichi Sankyo. These markets, with their growing populations and increasing healthcare spending, offer substantial potential for pharmaceutical sales. Establishing a strong presence in these regions could diversify Daiichi Sankyo's revenue streams and reduce its reliance on developed markets. Key emerging markets include China, India, and Brazil. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships and acquiring complementary businesses can accelerate Daiichi Sankyo's growth. Collaborations with biotechnology companies and research institutions can provide access to innovative technologies and drug candidates. Acquisitions can expand Daiichi Sankyo's product portfolio and geographic reach. The pharmaceutical industry is characterized by frequent mergers and acquisitions. Timeline: Ongoing.
- Advancements in Pain Management Therapies: Daiichi Sankyo's mirogabalin, a novel pain medication, addresses a significant unmet need in the treatment of neuropathic pain. The global pain management market is substantial, and effective new therapies are in high demand. Expanding the indications for mirogabalin and developing other pain management products could drive significant growth in this therapeutic area. The global pain management market is projected to reach $90 billion by 2027. Timeline: Ongoing.
Oportunidades
- Expansion into emerging markets.
- Strategic partnerships and acquisitions.
- Development of new therapies for unmet medical needs.
- Growth in the oncology market.
Amenazas
- Intense competition from other pharmaceutical companies.
- Patent expirations.
- Regulatory challenges.
- Economic downturns.
Ventajas competitivas
- Patents and intellectual property protection for its innovative drugs.
- Strong brand reputation and established relationships with healthcare providers.
- Extensive research and development capabilities.
- Global distribution network.
- Regulatory expertise and experience.
Acerca de DSKYF
Founded in 1899 and headquartered in Tokyo, Japan, Daiichi Sankyo Company, Limited is a global pharmaceutical organization dedicated to creating and supplying innovative pharmaceutical products. The company's operations span research and development, manufacturing, marketing, and sales of pharmaceuticals across the world. Daiichi Sankyo's product portfolio includes treatments in oncology, cardiovascular disease, pain management, and other therapeutic areas. Key products include trastuzumab deruxtecan (Enhertu), an anti-cancer agent, mirogabalin for pain, and edoxaban, an anticoagulant. The company also offers treatments for diabetes, osteoporosis, and various infectious diseases. Daiichi Sankyo has a significant presence in both developed and emerging markets. The company emphasizes research and development, particularly in oncology, and collaborates with other organizations to advance its pipeline. A collaboration with Guardant Health focuses on developing Guardant360 CDx as a companion diagnostic for Enhertu in non-small cell lung cancer. Daiichi Sankyo's long history and diverse product range contribute to its established position in the pharmaceutical industry.
Qué hacen
- Researches and develops pharmaceutical products.
- Manufactures pharmaceutical products.
- Imports pharmaceutical products.
- Markets pharmaceutical products.
- Sells pharmaceutical products.
- Offers treatments for oncology, cardiovascular diseases, pain management, and other therapeutic areas.
- Provides vaccines for various infectious diseases.
Modelo de Negocio
- Develops and patents innovative pharmaceutical products.
- Conducts clinical trials to demonstrate the safety and efficacy of its products.
- Obtains regulatory approvals from agencies such as the FDA and EMA.
- Manufactures and distributes its products globally.
- Markets and sells its products through a network of sales representatives and distributors.
Contexto de la Industria
Daiichi Sankyo operates in the global pharmaceutical industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory requirements. The industry is driven by innovation, with companies constantly seeking to develop new and improved treatments for various diseases. The market for oncology drugs is particularly competitive and lucrative. Daiichi Sankyo's focus on antibody drug conjugates positions it well within this landscape. The company competes with other major pharmaceutical companies, including CHALF, HLNCF, HOCPF, IPSEY, and OTSKY, all vying for market share in key therapeutic areas.
Clientes Clave
- Hospitals and clinics
- Pharmacies
- Healthcare providers
- Patients
- Government healthcare agencies
Finanzas
Gráfico e información
Precio de la acción de Daiichi Sankyo Company, Limited (DSKYF): Price data unavailable
Últimas noticias
-
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
BioPharma Dive · 20 feb 2026
-
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
benzinga · 7 ago 2024
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para DSKYF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para DSKYF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de DSKYF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Hiroyuki Okuzawa
Unknown
Information about Hiroyuki Okuzawa's background is not available in the provided context. Therefore, a detailed career history, education, previous roles, and credentials cannot be provided. Further research would be needed to provide a comprehensive biography.
Historial: Information about Hiroyuki Okuzawa's track record is not available in the provided context. Therefore, key achievements, strategic decisions, and company milestones under their leadership cannot be provided. Further research would be needed to provide a detailed analysis.
Información del mercado OTC de DSKYF
The OTC Other tier, where DSKYF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to meet minimum listing standards, which include requirements for financial reporting, corporate governance, and minimum share price. This lack of regulation increases the risk associated with investing in these companies.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in DSKYF.
- Lower liquidity can lead to price volatility and difficulty in executing trades.
- Lack of regulatory oversight compared to major exchanges.
- Potential for fraud or manipulation.
- Information asymmetry due to limited public information.
- Verify the company's registration and legal status.
- Attempt to locate and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal disputes involving the company.
- Established history dating back to 1899.
- Global presence and operations.
- Diverse product portfolio.
- Focus on research and development.
- Partnerships with reputable organizations.
Acciones de Daiichi Sankyo Company, Limited: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar DSKYF?
Daiichi Sankyo Company, Limited (DSKYF) actualmente tiene una puntuación IA de 55/100, indicando puntuación moderada. Fortaleza clave: Strong oncology pipeline with promising new therapies.. Riesgo principal a monitorear: Potential: Intense competition from other pharmaceutical companies.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de DSKYF?
DSKYF actualmente puntúa 55/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de DSKYF?
Los precios de DSKYF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre DSKYF?
La cobertura de analistas para DSKYF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en DSKYF?
Las categorías de riesgo para DSKYF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from other pharmaceutical companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de DSKYF?
La relación P/E para DSKYF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está DSKYF sobrevalorada o infravalorada?
Determinar si Daiichi Sankyo Company, Limited (DSKYF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de DSKYF?
Daiichi Sankyo Company, Limited (DSKYF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.